Acta Vascular Systems to Present at Medtech Insight's ``Investment In Innovation'' Conference.

Health/Medical Writers

Medtech Insight 2004 In3 San Francisco Conference

SAN FRANCISCO--(BUSINESS WIRE)--June 1, 2004

Acta Vascular will be presenting on June 8 at Medtech Insight's Prestigious "Investment In Innovation" Event, taking place June 8-9, 2004, at the Palace Hotel in San Francisco, California.

The Bay-area start-up in neurovascular technology will present details of its immediate revenue generation and product development plans. Acta acquired implantable products for the prevention and treatment of hemorrhagic stroke from a private French company, and plans to introduce these to the U.S. market in the Fall of this year.

"We're unique in that we began producing sales very early," says Tom Ross, President of Acta Vascular. "Our presentation will focus on the expected increased demand later this year with the U.S. launch, and how we will use the leverage of our worldwide recognized brand names and established distribution channels to carry our other product development projects successfully into the arena of hemorrhagic stroke."

Stroke strikes an estimated 700,000 victims in the U.S. annually, and is recognized as the #3 leading cause of death in the country. Over 163,000 hospital admissions are made with the diagnosis of hemorrhagic stroke, including ruptured aneurysms, arterio-venous malformations (AVMs), fistulas and other pathologies. While these diseases may be treated by open neurosurgery, a recent prospective controlled study(a) has shown that endovascular treatment significantly improves patient outcome. In endovascular procedures, an interventional neuroradiologist or other endovascular specialist accesses the intracranial pathology using catheters, guidewires and other devices. The endovascular treatment of most hemorrhagic disorders is performed by delivering an embolic device or agent to the site of the hemorrhage or pathology and blocking or greatly reducing blood flow.

Acta Vascular Systems can be reached for further information at 1-408-656-1585, via email at [e-mail] or on the web at www.actavascular.com.

(a) Lancet, October, 2002

About Medtech Insight

Medtech Insight's "Investment In Innovation (In3): A Preview of Early-Stage Medical Technology Companies" conferences are considered the premier forum for senior executives in the medical technology and investment community to preview emerging medtech companies in need of funding, acquisition and/or strategic partnership. In addition to conferences, Medtech Insight publishes the "medtech insight" newsletter, a monthly publication covering the latest trends and innovations in the medical technology industry, analyses of medtech markets through its Reports group, and offers custom consulting and market research. To register for the San Francisco conference or for more information on Medtech Insight, please call Scott Pantel at [phone] or [phone] toll-free in the U.S., e-mail [e-mail], or visit http://www.medtechinsight.com/in3-11.html.